Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
1994-4-8
|
pubmed:abstractText |
The aim of this study was to compare the effects of two different therapeutical regimens of IFN alpha-2a in patients with HCV related chronic liver disease. Eighty one patients with HCV chronic hepatitis with or without cirrhosis entered the study; 42 and 39 patients were treated with 3 or 6 MU IFN, respectively. The results show that: 1) 25/39 (64.1%) patients treated with 6 MU and 21/42 (50.0%) patients treated with 3 MU had a complete response defined as a decline in serum ALT levels to the normal range during therapy; 2) complete response to 6 MU treatment was observed independently of the presence or absence of cirrhosis; in the 3 MU group, a complete response was observed in 31.6% of patients with CAH + cirrhosis as compared with 68.2% of those with CAH alone (p < 0.03); and 3) at 1 year after the end of the treatment we observed persistent ALT normalization in 40.6% and 28.2% of patients treated with 6 or 3 MU, respectively, and absence, of HCV viraemia (HCV-RNA) in 7/10 patients with CAH and in 2/7 patients with CAH + cirrhosis, mostly in patients treated with 6 MU. In conclusion, 6 MU IFN dose is more effective than 3 MU in reducing disease activity in HCV chronic hepatitis, specially in patients with CAH + cirrhosis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Alanine Transaminase,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2a
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0392-0623
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
25
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
482-6
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8123895-Adult,
pubmed-meshheading:8123895-Aged,
pubmed-meshheading:8123895-Alanine Transaminase,
pubmed-meshheading:8123895-Chronic Disease,
pubmed-meshheading:8123895-Drug Administration Schedule,
pubmed-meshheading:8123895-Female,
pubmed-meshheading:8123895-Hepacivirus,
pubmed-meshheading:8123895-Hepatitis, Chronic,
pubmed-meshheading:8123895-Hepatitis C,
pubmed-meshheading:8123895-Humans,
pubmed-meshheading:8123895-Interferon-alpha,
pubmed-meshheading:8123895-Liver Cirrhosis,
pubmed-meshheading:8123895-Male,
pubmed-meshheading:8123895-Middle Aged,
pubmed-meshheading:8123895-RNA, Viral,
pubmed-meshheading:8123895-Recombinant Proteins,
pubmed-meshheading:8123895-Remission Induction
|
pubmed:articleTitle |
Recombinant human interferon alpha-2a therapy for chronic hepatitis C with or without cirrhosis: comparison of 3 or 6 MU for 1 year.
|
pubmed:affiliation |
Istituto di Medicina Generale e Metodologia Clinica, Facoltà di Medicina e Chirurgia, II Università di Napoli, Italy.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|